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ABSTRACT 
Background: Postprandial ipemia (PPL) is an independent predictor of early 
atherosclerosis and coronary artery disease. It is defined as a postprandial 
triglyceride (TG) level >80% higher than the fasting level. Brachial arterial reac- 
t ivity (BAR) is used to identify early-phase atherosclerosis. Data concerning 
whether orlistat improves PPL and endothelial function are lacking. 
Objective: The aim of this study was to determine the effects of orlistat on 
PPL and BAR in normolipidemic, obese women with normal glucose tolerance. 
Methods: This prospective, randomized, controlled study was conducted at 
Baskent University, Ankara, Turkey. Normolipidemic, obese women aged 18 to 
65 years with normal glucose tolerance were eligible for screening. On screen- 
ing, demographic information, anthropomorphic parameters (body mass index 
[BMI], waist circumference [WC], hip circumference, waist-hip ratio), BAR, lab- 
oratory test results (level of insulin resistance assessed using the homeostasis 
model assessment-insulin resistance [HOMA-IR] index, serum lipid profile, fast- 
ing plasma levels of glucose and insulin [FPI]), and oral fat-loading test results 
were recorded as baseline values. The primary end points were the effects of orli- 
stat + diet on PPL (assessed using the AUC of TG) and BAR. Women found on 
screening to be PPL positive were randomly assigned in a 2:1 ratio to treatment 
with orlistat 120 mg TID plus low-calorie diet (600-kcal/d eficit; minimum, 1200 
kcal/d) or low-calorie diet only (control) for 12 weeks. After 12 weeks, all of the 
above assessments were repeated, and AUC values for lipid parameters were cal- 
culated as secondary outcome measures. To assess tolerability and compliance, 
women were monitored by telephone ach week and instructed to return every 
4 weeks for clinic visits. 
Results: Twenty-seven women were identified as PPL posit ive and assigned 
to the orlistat + diet group (18 subjects) or the control group (9) (mean [SD] age, 
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45.9 [2.3] years; mean [SD] weight, 87.4 [2.5] kg; mean [SD] BMI, 36.0 [0.8] kg/m2). 
Treatment with orlistat + diet was associated with significantly greater changes 
from baseline compared with controls in WC (P = 0.003), fasting and postprandial 
serum TG levels (P = 0.012 and P< 0.001, respectively), FPI level (P = 0.001), and 
HOMA-IR index (P < 0.001). Logistic regression analysis found that 12 weeks of 
treatment with orlistat + diet was associated with a numeric, but statistically non- 
significant, 4.1-fold change in PPL, which was independent of reductions from 
baseline in weight and WC. Neither treatment was associated with significant 
changes from baseline in BAR. The prevalences of gastrointestinal symptoms 
previously found to be related to orlistat use were statistically similar between 
the orlistat + diet and control groups (9 [50.0%] vs 3 [33.3%] subjects). 
Conclusions: The results of this small study in normolipidemic, obese 
women with normal glucose tolerance suggest that 12 weeks of treatment with 
orlistat 120 mg/d plus low-calorie diet was associated with a numeric, but statis- 
tically nonsignificant, 4.1-fold change from baseline in PPL, which was indepen- 
dent of reductions from baseline in weight and WC. Treatment with orlistat + diet 
was associated with significant effects on WC, TG, and level of insulin resis- 
tance, but not BAR. (Curr Ther Res Clin Exp. 2006;67:159-173) Copyright © 2006 
Excerpta Medica, Inc. 
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INTRODUCTION 
Obesity is a serious health concern affecting >300 million people worldwide, and 
its prevalence increased by >50% between 1998 and 2004.1 Obesity and associ- 
ated lipid abnormalities, such as decreased serum levels of high-density lipopro- 
tein cholesterol (HDL-C); increased serum triglyceride (TG) level; and the forma- 
tion of small, dense particles of low-density lipoprotein cholesterol (LDL-C) in 
blood, have been identified as risk factors for coronary artery disease (CAD). 2 
Postprandial lipemia (PPL), defined as a postprandial TG level ~80% higher 
than the fasting level (independent of obesity), is an important risk factor for ath- 
erosclerosis and CAD. 3 Guerci et al 4 studied the effects on postprandial responses 
to an oral fat-loading test in 17 normotriglyceridemic, android (abdominal obesity 
lie, waist-hip ratio (WHR) >0.85 for women and >0.95 for men]) obese subjects 
with normal glucose tolerance and 33 normal-weight controls. They found that 
abnormal postprandial serum lipoprotein levels were an important risk factor for 
atherosclerosis, even in people with normal blood lipid levels. 
Abnormal postprandial response to fat-loading challenge has been detected 
in obese patients with normal TG levels. Guerci et al 4 found that the AUC for chy- 
lomicron TG was similar between obese patients and normal-weight controls, 
indicating adequate lipolytic activity; in contrast, the AUC for nonchylomicron 
TG was significantly greater in obese patients compared with controls. However, 
the differentiation f chylomicron subfractions requires ophisticated methods 
not used in the present study. 
160 
I. Turker et al. 
Brachial artery reactivity (BAR) is used for assessing endothelial dysfunc- 
tion, identifying early-phase atherosclerosis and CAD risk, and monitoring the 
effects of CAD treatments. 4 It is assessed noninvasively using high-frequency 
ultrasound, 5 which follows changes in vessel diameter in response to in- 
creased flow and to glyceryl trinitrate (GTN). In arteries lined with healthy 
endothelium, increased flow causes dilatation of the vessels via release of 
endothelium-dependent r laxing factor. This mechanism fails in endothelial 
dysfunction. In contrast, GTN causes vasodilatation by direct action on the 
smooth muscle; its effect, therefore, is independent of the endothelium. BAR 
can be used to determine whether endothelial dysfunction is present in sub- 
jects at high risk for atherosclerosis before clinical evidence of vascular dis- 
ease develops. 5 
Orlistat is a pancreatic lipase inhibitor indicated for the treatment ofobesity 
and its complications. 6 Data concerning whether orlistat improves PPL and 
endothelial function are lacking. The aim of this study was to determine the 
effects of orlistat on PPL and BAR in normolipidemic, obese women with normal 
glucose tolerance. 
SUBJECTS AND METHODS 
This prospective, randomized, controlled study was conducted at Baskent 
University, Ankara, Turkey. The study protocol was approved by the ethics 
committee of the Baskent University Faculty of Medicine. The study was con- 
ducted in accordance with the Good Clinical Practice Guidelines 7 and the 
Declaration of Helsinki and its amendments. 8 
Inclusion and Exclusion Criteria 
Subjects were recruited by one of the investigators (I.T.) from the Department 
of Endocrinology and Metabolic Diseases outpatient clinic from August 2001 to 
December 2002. Normolipidemic, obese female volunteers aged 18 to 65 years 
with normal glucose tolerance and PPL were eligible to participate in the study. 
Subjects were excluded if they had any systemic illness, such as diabetes 
mellitus (DM); hypertension (blood pressure, _>140/_>90 mm Hg); CAD; and/or 
any type of thyroid, hepatic, and/or renal disease. Additional factors known to 
affect BAR (congestive heart failure, anemia, and/or smoking history) were con- 
sidered grounds for exclusion from the study. We also planned to exclude 
women with a family history of lipid metabolic disorder. Subjects were excluded 
if they had ever received pharmacologic therapy for weight control and/or lipid- 
lowering therapy, or were receiving treatment with oral contraceptives, aspirin, 
complex vitamins, or any medication known to affect lipid metabolism (eg, eze- 
timibe, fibrates, metformin, iacin, orlistat, sibutramine, thiazolidinediones). Preg- 
nant or breastfeeding women were also excluded. 
Eligible subjects provided written informed consent and were compensated 
for their participation. 
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Screening Visit 
Each subject was seen by the same physician (I.T.), who performed a physi- 
cal examination (including heart rate and sitting blood pressure measurements 
[Erkameter 3000, Erka Kallmeyer GmbH & Co. KG, Bad Tolz, Germany] [the 
mean of 3 measurements was used]) and anthropomorphic measures (weight, 
waist circumference [WC], and hip circumference [HC]). Demographic nforma- 
tion was recorded, and body mass index (BMI) and WHR were calculated by the 
physician. 
Each woman presented for screening after a 12-hour overnight fast and com- 
pleted a fat-loading test. For this test, each subject consumed a meal that con- 
tained 60 g/m 2 fat and 1800 to 2200 kcal (depending on body surface area), with 
64% of total calories from fat; 18%, from carbohydrates; and 18%, from protein. 
Only water was allowed for 8 hours after the test meal. 
To determine l vels of fasting plasma glucose (FPG) and serum levels of total 
cholesterol (TC), LDL-C, HDL-C, TG, and apolipoprotein (apo) B, blood samples 
were drawn by a nurse into Vacutainer tubes (Becton, Dickinson and Company, 
Franklin Lakes, New Jersey) before fat loading and at 2, 4, 6, and 8 hours there- 
after. These levels were determined enzymatically using a Hitachi Modular 
System (Roche Molecular Biochemicals, Roche Diagnostics GmbH, Mannheim, 
Germany). Fasting plasma insulin (FPI) levels were determined using enzyme- 
linked immunosorbent assay (Immulite, Diagnostic Products Corporation, Los 
Angeles, California). Level of insulin resistance (IR) was calculated using the 
homeostasis model assessment-insulin resistance (HOMA-IR) index, as defined 
by Matthews et a19: 
HOMA-IR index = FPI (mU/L) × FPG (mmol/L)/22.5 
Normolipidemic was defined as serum levels of LDL-C <130 mg/dL (<3.38 mmol/L), 
HDL-C >50 mg/dL (>1.29 mmol/L), and TG <150 mg/dL (<1.69 mmol/L). Obese 
was defined as BMI ~30 kg/m 2. Normal glucose tolerance was defined as FPG level 
<110 mg/dL (<6.1 mmol/L) and 2-hour 75-g oral glucose tolerance test (OGTT) 
result <140 mg/dL (<7.76 mmol/L). Each subject was also identified as PPL positive 
(postprandial TG level ~80% higher than the fasting level) or PPL negative. 
After 10 hours of fasting and at 4 hours postprandially, endothelial function 
was assessed using BAR, which measured flow-mediated ndothelium-dependent 
(FMD) vasodilatation (brachial artery diameter and velocity [blood flow]). 
BAR was performed using a Siemens Sonoline Elegra ultrasound device 
(Siemens AG, Munich, Germany), as detailed in previous reports. 1°,11 The same 
radiologist (I.K.) performed BAR in each subject and was blinded to treatment 
assignment. 
Treatments  
Women identified as PPL positive were randomly assigned to the group re- 
ceiving orlistat 360 mg/d (one 120-mg capsule TID with meals) plus low-calorie 
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diet (600-kcal/d eficit; minimum, 1200 kcal/d 12) or the control group (low-calorie 
diet only; no placebo administered). Randomization was performed in a 2:1 
ratio according to the order in which the women were enrolled in the study. 
Both groups received treatment for 12 weeks. 
Assessments of Treatment Effects on Postprandial 
Lipemia and Brachial Artery Reactivity 
The primary end points were the effects of orlistat reatment on PPL (assessed 
using the AUC of TG [AUC-TG] 13) and BAR. Secondary end points included changes 
in anthropomorphic parameters, lipid levels, and AUC values for non-TG lipids. 
After 12 weeks, subjects underwent repeated assessments of serum lipid 
parameters, oral fat-loading testing, and BAR. AUC values for lipid parameters 
were calculated. The trapezoidal rule was used to calculate the incremental AUCs 
for serum TG and lipoproteins, with the fasting value for each parameter used as 
the baseline value. 14 Percentage changes from baseline in brachial artery diame- 
ter and blood flow were calculated as described by previous investigators. 1°,11 
Changes from baseline in anthropomorphic measures were calculated. 
Tolerability and Compliance Assessments 
To assess tolerabi l i ty and compliance, women were monitored by telephone 
each week and instructed to return every 4 weeks for clinic visits. Subjects were 
asked direct ly about adverse events at each clinic vis it  and by telephone. If a 
subject mentioned experiencing an adverse event, she underwent physical 
examination and laboratory testing. Unused pills were counted at each visit; if 
the count was high (>4), the subject was quest ioned further. 
Statistical Analysis 
Statistical comparisons and correlation analysis were performed. We as- 
sumed that subjects receiving orlistat + diet would lose 5% of their initial weight 
and expected that half of this weight loss could be attr ibuted to diet. Taking into 
account that the mean weight of the women in this study was -90 kg, the 
expected amounts of weight loss were 4.5 _+ 2.0 kg in the orlistat + diet group 
and 2.3 _+ 2.0 kg in the control group. We used the 2002 release of Statistical and 
Power Analysis (NCSS Inc., Kaysville, Utah) to determine the sample size and 
found that 18 subjects in the orlistat + diet group and 9 subjects in the control 
group would be necessary for 95% power to detect differences in weight of 2.25 kg 
at an c¢ level of 0.05. 
The t test was used to assess differences in anthropomorphic  measures and 
blood levels between the orlistat + diet and control groups. Homogeneity of 
variances was analyzed using the Levene test. The paired-samples t test was 
used for intragroup comparisons of findings before versus after treatment. The 
independent-samples t test was used to make intergroup comparisons of 
parameter changes from before to after treatment. P values <0.05 were consid- 
ered statistically significant. Logistic regression analysis was used to assess 
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whether treatment with orlistat + diet had an independent effect on PPL. 
Correlations between AUC-TG and WC, fasting TG and FPI levels, and HOMA-IR 
index were tested using the Pearson product moment correlation. SPSS version 
11.0 (SPSS Inc., Chicago, Illinois) was used for data manipulation and calculations. 
All results are expressed as mean (SD). 
RESULTS 
Study Population 
Thirty-four women were screened; based on the results of the initial fat- 
loading test, 27 subjects were identified as PPL positive; 7, PPL negative. Baseline 
demographic variables were not significantly different between PPL-positive 
subjects (included in the study) versus PPL-negative subjects (not studied) 
(data not shown). Demographic and baseline clinical characteristics were not 
significantly different between the orlistat + diet and control groups. 
Of the 27 women identified as PPL positive and included in the study (mean 
[SD] age, 45.9 [2.3] years; 27 [100%] Turkish; mean [SD] weight, 87.4 [2.5] kg; 
mean [SD] BMI, 36.0 [0.8] kg/m2), 18 were assigned to the orlistat + diet group; 
9, to the control group. All 27 subjects completed the study. 
Treatment Effects on Postprandial Lipemia and 
Brachial Artery Reactivity 
Comparison mean (SD) changes from baseline in AUC-TG (which reflects 
PPL 13) revealed a significant difference between the orlistat + diet and control 
groups (P < 0.001). No significant between-group differences in changes from 
baseline in AUC-TC, AUC-LDL-C, AUC-HDL-C, or AUC-apoB were found (Table I). 
The figure shows the changes in PPL severity (ie, percentage decreases in the 
differences between postprandial nd fasting TG levels). 
Orlistat reatment was associated with a numeric, but statistically nonsignifi- 
cant, 4.1-fold change from baseline in PPL, which was independent of reductions 
from baseline in weight and WC. Table II shows the effects of treatment on PPL. 
Analysis to identify factors associated with AUC-TG found strong positive corre- 
lations between AUC-TG and fasting TG and FPI levels and HOMA-IR index. 
Table III shows the effects of treatment on BAR. Neither group had signifi- 
cant changes from baseline in BAR. 
Secondary End Points 
Table IV shows the changes from baseline in anthropomorphic f ndings, lipid 
parameters, FPI level, and HOMA-IR index. At 12 weeks, the following parame- 
ters were significantly increased from baseline in the orlistat + diet group: 
weight (P < 0.001); BMI (P < 0.001); WC (P < 0.001); HC (P < 0.001); WHR (P < 
0.001); fasting levels of TC (P < 0.02) and TG (P < 0.02); postprandial TG level 
(P < 0.001); FPI (P < 0.02); and HOMA-IR index (P < 0.02). In the control group, 
only postprandial HDL-C was decreased significantly at 12 weeks (P < 0.01). 
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Table I. Changes from baseline in lipid AUCs after 12 weeks of treatment with orlistat 
120 mg/d plus low-calorie diet or low-calorie diet alone (control) in normolipi- 
demic, obese women with normal glucose tolerance.* Values are mean (SD). 
Orlistat + Diet Control 
Lipid AUC (n = 18) (n = 9) P 
AUC-TG, mmol.  min/L 
AUC-TC, mmol.  min/L 
AUC-LDL-C, mmol.  min/L 
AUC-HDL-C, mmol.  min/L 
AUC-apoB, g • min/L 
-2.73 (0.42) +1.18 (0.03) <0.001 
-1.06 (0.13) -1.01 (0.18) NS 
-0.15 (0.08) -0.49 (0.44) NS 
-0.07 (0.11) -0.88 (0.04) NS 
-0.14 (0.01) +0.32 (0.17) NS 
TG = triglycerides; TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C = high- 
density lipoprotein cholesterol; apoB = apolipoprotein B. 
*To convert o mg/dL, divide by the following: TG, 0.01129; LDL-C and HDL-C, 0.02586; and apoB, 0.01 .is 
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Figure. Postprandial lipemia severity (ie, percentage decreases in the differences 
between postprandial and fasting tr iglyceride [TG] levels) before and after 
12 weeks of administrat ion of orl istat 120 mg/d plus low-calorie diet or low- 
calorie diet alone (control) in normolipidemic, obese women with normal 
glucose tolerance. 
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Table II. Effects on postprandial lipemia, shown by correlation- 
analysis results relative to triglyceride (TG) AUC, in normo- 
lipidemic, obese women with normal glucose tolerance 
after 12 weeks of treatment with orlistat 120 mg/d plus 
low-calorie diet (n = 18). 
Parameter r P 
Fasting TG level at baseline 
Fasting TG level at 12 weeks 
FPI level at 12 weeks 
HOMA-IR index at 12 weeks 
-0.438 <0.05 
0.756 <0.001 
0.537 <0.01 
0.592 <0.001 
FPI = fasting plasma insulin; HOMA-IR = homeostasis model assessment-insulin 
resistance. 
Table III. Percentage changes from baseline in fasting and postpran- 
dial brachial artery reactivity (BAR) findings after 12 weeks 
of treatment with orlistat 120 mg/d plus low-calorie diet 
or low-calorie diet alone (control) in normolipidemic, obese 
women with normal glucose tolerance.* Values are mean 
(SD) %A. 
Orlistat + Diet Control 
BAR Parameter (n = 18) (n = 9) 
Fasting 
Diameter +2.2 (0.4) +5.0 (0.5) 
Flow +16.4 (3.3) -3.5 (39.4) 
Postprandial 
Diameter -0.1 (0.1) +4.3 (1.6) 
Flow +23.5 (0.8) -7.8 (34.0) 
*No significant between-group differences were found. 
The following changes from baseline were significantly greater in the 
orlistat + diet group compared with those in the control group: WC (P = 0.003); 
fasting TG (P = 0.012); FPI (P = 0.001); postprandial TG level (P < 0.001); and 
HOMA-IR index (P< 0.001). Neither group had significant changes from baseline 
in weight, fasting or postprandial non-TG lipid levels, or level of IR. 
Tolerability and Compliance 
The prevalence of gastrointestinal symptoms reported in the orlistat + diet 
and control groups were oily stool (4 and 2 subjects, respectively), oily spotting 
(3 and 1 subject, respectively), fecal urgency (1 in the orlistat + diet group), and 
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fecal incontinence (1 in the orlistat + diet group). The overall prevalences ofadverse 
events were statistically similar between the orlistat + diet and control groups 
(9 [50.0%] vs 3 [33.3%]). These events were reported uring the first 2 weeks of 
the study, before subjects became accustomed to the low-fat diet, and none of 
them led to treatment discontinuation. Overall compliance was _>90.2%. 
DISCUSSION 
Obesity treatment might be beneficial in the primary prevention of CAD. 2 An analy- 
sis 16 of pooled data from five 1-year, randomized, ouble-blind, placebo-controlled 
trials of orlistat 360 mg/d in conjunction with a hypocaloric diet in 3132 obese 
patients found that this treatment had positive effects on the serum levels of TC, 
LDL-C, TG, and apoB, and other risk factors (blood pressure, WC, and OGTT 
results). In a multicenter, andomized, double-blind, placebo-controlled study, 
Muls et a117 investigated 294 overweight or obese patients with concomitant 
hypercholesterolemia who received orlistat 360 mg/d or placebo for 24 weeks 
after a 2-week, single-blind, run-in period. They found that orlistat treatment 
was associated with significant decreases in weight (-6.8%) (P < 0.001) and 
serum levels of TC (-11.9%) (P< 0.001) and LDL-C (-17.6%) (P< 0.001). Improve- 
ment in LDL-C was independent of weight loss. In contrast, in the normo- 
lipidemic women in the present 12-week study, no significant changes from 
baseline in weight or LDL-C were found. These differing results might have been 
due to the differences in subjects' demographic characteristics and baseline 
lipoprotein values and/or the study design and/or duration. 
A randomized, placebo-controlled study in 128 patients with syndrome X
conducted by Reaven et a118 found that, in addition to significant weight loss, 
1 year of treatment with orlistat 120 mg TID was associated with improvements 
in CAD risk factors, such as increased HDL-C (P < 0.001) and decreased LDL-C/ 
HDL-C ratio (P< 0.001), TG (P< 0.001), and FPI (P = 0.019). Other research 19 sug- 
gests that orlistat might prevent glucose intolerance and/or type 2 DM in pa- 
tients with obesity. In a pooled analysis 19 of data from 3 multicenter (39 US and 
European research centers), randomized, ouble-blind, clinical trials, 675 adults 
with obesity were administered orlistat or placebo for 104 weeks. The rate of 
glucose normalization was significantly higher in the patients who received orli- 
stat compared with those who received placebo (71.6% vs 49.1%; P = 0.04). 
Torgerson et al 1 assessed the effects of 4 years of treatment with orlistat on the 
prevention of DM in -3000 subjects with obesity in a prospective, randomized, 
double-blind study. After 4 years of study drug administration, the cumulative 
incidence of type 2 DM was 6.2% with orlistat versus 9.0% with placebo, with 
a corresponding risk reduction of 37.3% (P < 0.004). The investigators also 
observed that orlistat was associated with significantly reduced blood pressure 
(A, -4.9/-2.6 mm Hg; P < 0.01), WC (A, -6.4 cm; P < 0.01), and serum LDL-C 
(A, -12.8 mg/dL; P < 0.01). The atherogenic alterations found in the present 
study might have been attributed partly to IR associated with obesity. We pro- 
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pose that the oral fat-loading test was useful for finding abnormalit ies in lipid 
metabolism. 
PPL has been found to be an early marker of atherosclerosis and CAD. 4 In this 
study, PPL was defined as a postprandial serum TG level _>80% higher than the 
fasting level. 3 Guerci et al 4 found that the mean (SD) AUC for nonchylomicron 
TG after 8-hour oral fat loading was significantly greater in the obese subjects 
than in the controls (512 [135] vs 429 [141] mmol • min/L; P< 0.01). Overall, the 
obese subjects had an abnormal PPL response, indicated by a significantly 
higher postprandial serum TG level in the nonchylomicron subfraction com- 
pared with that in controls. These atherogenic alterations were attr ibuted 
partly to IR associated with obesity in that study. The mean (SD) HOMA-IR index 
was 1.96 (0.83) in 5 obese men; 2.93 (1.22) in 12 obese women; 1.17 (0.47) in 
21 normal-weight men; and 0.99 (0.32) in 12 normal-weight women (P < 0.05). 
Those investigators proposed that the oral fat-loading test was useful for 
unmasking abnormalit ies of lipid metabol ism because the presence of PPL has 
been associated with increased CAD risk. 4 In the present study, on logistic- 
regression analysis, whose accuracy in predicting the presence or absence of 
CAD is 68%, 20 the maximal TG levels at 6 and 8 hours after the meal were signif- 
icantly different between groups (P < 0.001). 
Pirro et a121 studied the interaction between fasting and postprandial lipid 
profiles after menopause. They examined postprandial changes in several ipid 
parameters in 2 age-matched groups of postmenopausal  women (16 with mixed 
hyperlipidemia, 17 with common hypercholesterolemia, and 17 with normolipi- 
demia) who underwent a standardized oral fat-loading test. The magnitude of 
postprandial ipemia, expressed as mean (SD) 8-hour incremental AUC-TG 
(i[AUC]-TG), was significantly greater in women with mixed hyperl ipidemia 
(1326 [372] mg. h/dL) than in women with normolipidemia (484 [384] mg. h/dL) 
or hypercholesterolemia (473 [223] mg • h/dL) (both, P < 0.001), and these dif- 
ferences were significant after adjustment for BMI and FPI level. In women with 
mixed hyperlipidemia, postprandial HDL-C, apoA, and LDL particle size were 
significantly decreased from fasting values. Both hypercholesterolemic and nor- 
molipidemic women had postprandial HDL-C and apoA levels that were signifi- 
cantly decreased from fasting levels, but LDL particle size was not significantly 
changed. Those investigators found that WHR, fasting TG level, and FPI level 
were independent predictors of PPL in women with hyperlipidemia. Vansant et 
a122 investigated factors related to PPL in 93 obese women in a randomized, 
double-blind clinical study and found that age, fasting TG level, ratio of intra- 
abdominal fat to subcutaneous abdominal fat, and level of IR were independent 
determinants of PPL. The same study found that menopausal  state, BMI, WHR, 
and apoE polymorphism had no significant influence on PPL in obese women. 
Reitsma et a113 studied the effects of 8 weeks of treatment with orlistat 120 mg 
TID on PPL and LDL-C metabolism in 17 hyperlipidemic patients in a randomized 
clinical study. In addition to weight-reducing and lipid-lowering effects in the fast- 
ing state, and decreases in plasma TC (%A, 8%; P = 0.006), LDL-C (%A, 9%; P = 
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0.002), and apoB (%A, 10%; P = 0.002) levels, those investigators found that orli- 
stat use was associated with reduced severity of PPL (27% decrease in the dif- 
ference between postprandial nd fasting TG) without significantly altering fast- 
ing serum TG or HDL-C level. Another andomized clinical study 23 looked at the 
acute effects of single-dose (120 mg) treatment with orlistat on PPL and free 
fatty acids in 63 overweight men and women with type 2 DM. Those investiga- 
tors found that i(AUC)-TG was significantly lower at 2 hours after a single 
dose of orlistat 120 mg compared with placebo (5.8 vs 5.7 mmol. h/L; P = 0.04). 
In the present study, after 12 weeks of orlistat reatment, PPL was changed by 
4.1-fold, but this change was not statistically significant. Comparisons of AUC 
changes from baseline to after treatment found significantly lower AUC-TG val- 
ues in the orlistat + diet group compared with controls. We detected strong pos- 
itive correlations between AUC-TG and fasting TG, FPI, and HOMA-IR index. 
A MEDLINE search (key terms: orlistat, brachial artery reactivity, and post- 
prandial ipemia; years: 1990-2004) for relative literature did not identify any 
published studies of the effects of orlistat on BAR. However, the effects of 
fibric-acid derivatives and lipid-lowering therapies on BAR have been exten- 
sively researched. 24-27 Evans et a124 found, in a 12-week, double-blind study 
in 20 patients with type 2 DM, that ciprofibrate 100 mg QD was associated 
with decreased fasting serum TG and TG content in lipoproteins and with 
improved endothelial function, as assessed using BAR. After ciprofibrate treat- 
ment, mean (SD) fasting and postprandial FMD values were significantly in- 
creased from baseline (from 3.8% [1.8%] and 1.8% [1.3%], respectively, to 4.8% 
[1.1%] and 3.4% [1.1%], respectively; P < 0.05). Those investigators concluded 
that fibrate improved fasting and postprandial endothelial function in those 
patients with type 2 DM. Van Venrooij et a125 prescribed a 30-week course of 
aggressive lipid-lowering treatment with atorvastatin 10 to 80 mg in 103 patients 
with type 2 DM without known CAD in a randomized, double-blind, placebo- 
controlled trial. Endothelial function was not significantly changed (mean FMD, 
3.16%; mean response on sublingual nitroglycerin, 6.58%; P = NS) even though 
the patients' serum lipid and lipoprotein levels decreased significantly (by 46%; 
P < 0.001). Those investigators concluded that endothelial function had been 
irreversibly impaired due to long-term (mean duration, 11.5 years) type 2 DM, 
and that 30 weeks of treatment was inadequate to detect any effect of atorva- 
statin on BAR. 
To investigate the effects of TG elevation in isolation from hyperinsulinemia, 
Gokce et a126 examined vascular esponses to an IV infusion of a TG emulsion in 
14 healthy subjects in a randomized clinical study. The subjects consumed 
high-fat and low-fat meals on separate days. Mean (SD) FMD was significantly 
decreased after the high-fat meal only (from 14.7% [8.3%] to 10.6% [6.2%]; P < 
0.001), and the decrease was associated with a 6% increase from baseline in 
brachial artery diameter (from 3.5 [0.8] to 3.7 [0.8] mm; P< 0.001), but not with 
a significant decrease in arterial diameter, during hyperemia. Serum TG and 
insulin levels were increased with the administration of the high-fat meal (by 
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94% and 438%, respectively). Serum TG level was increased by 197% with the 
administration of the TG emulsion, but serum insulin level was not significantly 
increased. No significant change in FMD or nitroglycerine-mediated vasodila- 
tion was found. Because oral administration of TG was necessary  for insulin 
secretion, those investigators concluded that IV administration of TG had no 
direct effect on endothelial function in those volunteers. Lundman et a126 
observed different results in 70 healthy men who received TG emulsion. They 
found that hypertr iglyceridemia significantly impaired both FMD (mean [SD], 
from 7.1% [3.0%] to 1.6% [2.6%]; P < 0.001) and nitroglycerine-dependent 
vasodilation (mean [SD], from 20.5% [5.8%] to 11.5% [3.2%]; P < 0.002) from 
before to after 1 hour of infusion of intralipid. Studies of endothelial function 
assessed using BAR in healthy subjects continue to produce conflicting 
results. 24-27 We observed no significant changes in BAR from before to after 
12 weeks of treatment in the orlistat + diet or control group, perhaps because a
12-week course of orlistat 360 mg/d might not have been sufficient for changes 
in BAR to occur or be detected. It may also be that the sample sizes were too 
small to reveal such alterations. The major limitation in the study design was 
the lack of blinding of the subjects and investigators, other than the radiologist, 
to treatment assignment. 
Comparisons of parameter changes from before to after treatment found sig- 
nificant decreases in fasting and postprandial TG levels in the orlistat + diet 
group, whereas no such improvements were observed in the control group. 
Intergroup comparisons revealed no significant differences in changes from 
baseline in weight or serum levels of TC, LDL-C, or HDL-C. Compared with the 
control group, the orlistat + diet group had significantly greater improvements 
in WC (P= 0.003), insulin level (P= 0.001), and HOMA-IR index (P< 0.001). These 
differences are interesting in light of the fact that all subjects in the orlistat + 
diet group (and in the study as a whole) were normolipidemic, obese women 
with normal glucose tolerance. Thus, treatment with orlistat + diet was associ- 
ated with positive effects on CAD risk factors in this group of obese but other- 
wise clinically healthy women with PPL. Based on the results from the present 
study, orlistat might be an effective treatment for PPL in this patient group. 
Randomized, blinded, controlled studies of longer duration and larger sample 
size are needed to clarify the effects of orlistat use on PPL and BAR. 
CONCLUSIONS 
The results of this small study in normolipidemic, obese women with normal 
glucose tolerance suggest hat 12 weeks of treatment with orlistat 120 mg TID 
plus low-calorie diet was associated with a numeric, but statistically nonsignif- 
icant, 4.1-fold change from baseline in PPL, which was independent of reduc- 
tions from baseline in weight and WC. Treatment with orlistat + diet was asso- 
ciated with significant effects on WC, TG, and level of IR, but not significant 
changes in BAR. 
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